KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non-Current Liabilities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.2 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $3.2 million at Xenon Pharmaceuticals, up from $3.2 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $3.2 million in Q4 2025, with the low at $3.2 million in Q3 2025.